Efficacy of Dupilumab on Facilitated Food Introduction in Eosinophilic Esophagitis
Key facts
- Who runs it
- Children's Hospital of Philadelphia
- Where
- Philadelphia, United StatesSee the site
- Trial code
- Status
- Completed
- Phase
- Phase 4
- People taking part
- 21 people enrolled
- Started
- 16 Jun 2022
- Ended
- 21 Jan 2025
- Type of study
- Interventional
- Treatments tested
- Eosinophilic Esophagitis (EoE) food introduction-1st
- Eosinophilic Esophagitis (E0E) food introduction-2nd
- Eosinophilic Esophagitis (EoE) Food introduction-3rd dose
- Dupilumab
- Record updated
- 10 November 2025
Who can take part
- Age
- 6 years to 25 years
- Sex
- Women and men
- Healthy volunteers
- Cannot take part
The registry criteria, word for word
Show all 31 criteriaShow less
Who can take part
- Males or females age 6 to 25 years
- Diagnosis of Eosinophilic Esophagitis based on the most recent international consensus definition (Dellon et al, Gastroenterology 2019); History of endoscopy with a peak count of >15 eosinophils per high powered field meeting consensus criteria for Eosinophilic Esophagitis1
- History of either milk, egg, soy or wheat induced EoE based on the following criteria in the last two years; Addition of a single food lead to exacerbation of esophageal eosinophilia (increase of greater than 15 eos/hpf) or; Removal of a single food lead to normalization of biopsy (esophageal eosinophilia showed less than 6 eos/hpf) AND; History of either milk, egg, soy or wheat induced EoE based on introduction of the food and symptoms in the last 12 months
- Weight > 10 kg
- Ability to remain on stable dose of Proton Pump Inhibitor (PPI) therapy throughout the study
- Girls > 11 years of age must have a negative urine/serum pregnancy test
- Parental/guardian permission (informed consent) and if appropriate, child assent
Who cannot take part
- Systemic immunosuppressant usage in prior 3 months
- Therapy with biologic molecule (e.g. omalizumab, infliximab) in prior 12 months
- Subjects undergoing any type of immunotherapy to any food (oral immunotherapy, sublingual immunotherapy, specific oral tolerance induction) within 3 months prior to Visit 1
- Participation in another clinical intervention study in the three months prior to Visit 1
- Subjects on any experimental drugs or treatments
- Treatment with a live (attenuated) vaccine within 4 weeks before the baseline visit or throughout the trial
- Women of children bearing potential (WOCBP) who are unwilling to practice highly effective contraception prior to the initial dose/start of the first treatment, during the study, and for at least 12 weeks after the last dose. This includes female patients who experience menarche during the study duration and who are unwilling to follow the precautions for WOCBP
- Chronic or acute infection requiring treatment with systemic antibiotic, antivirals, or antifungal within 2 weeks of baseline visits; Patients maybe rescreened after infection resolves
- Tracheo-esophageal fistulas, inflammatory bowel disease, Barrett's disease, or other significant inflammatory disease of the gastrointestinal tract
- History of significant esophageal procedures e.g. sclerotherapy or esophagectomy
- Active IgE- mediated milk, egg, wheat or soy allergy based on skin test or history (if those foods are being introduced back into the diet)
- Allergy or known hypersensitivity to the dupilumab
- Subjects (or parents of subjects) with obvious excessive anxiety and unlikely to cope with the conditions of an upper Endoscopy and biopsy
- Past or current disease(s), which in the opinion of the Investigator or the Sponsor, may affect the subject's participation in this study, including but not limited to active autoimmune disorders, immunodeficiency, malignancy, uncontrolled diseases (hypertension, psychiatric (especially anxiety), cardiac), or other disorders (e.g., liver, gastrointestinal, kidney, cardiovascular, pulmonary disease, or blood disorders)
- Participants with active or suspected parasitic infection are excluded
- Biopsy evidence of eosinophilic infiltration in any other organ system
- Narrow caliber esophagus defined as the inability to pass a 9.5 mm endoscopy into the esophagus
- IgE mediated reaction to food (milk, egg, soy or wheat) being introduced in the last 12 months
- Any factors that may pose a significant risk for undergoing anesthesia/sedation
- Subjects unable to follow the protocol and the protocol requirements
- Subjects unable to read/understand English or follow the protocol and the protocol requirements
- Subjects unable to read/understand English or follow the protocol and the protocol requirements
- Major elective surgeries are prohibited during the study
- Female patients who are pregnant, breastfeeding, or planning to become pregnant or breastfeed during the study
Where in United States
- Children's Hospital of PhiladelphiaPhiladelphia, United States
About the trial
What the trial wants to find out
Eosinophilic Esophagitis (EoE) is a food driven non-immunoglobulin E (IgE) mediated disease involving eosinophils and type 2 inflammation. Current therapies include diet and the off label use of medications including proton pump inhibitors, topical steroids or biologics. Food elimination creates a decrease quality of life in many children. The goal of the study is to examine a T2 inhibitor (dupilumab) can allow successful reintroduction of allergic EoE foods into the diet. This is a single site study, enrolling subjects 6 to 25 years of age.
The group in the trial
- Study GroupTreatment being tested
30 patients will be given dupilumab (dose based on current approved doses or used in current EoE clinical trial, q weekly dosing) and monitored for clinical response after 12 weeks of therapy) Dosing: \>12 years of age \> 40 kg 300 SQ weekly 30- 40 kg 300 mg SQ Q2 weeks 15-29.9 kg 200 mg SQ Q2 weeks 6-11 years of age 5-15 kg 100 mg SQ Q2W 15-30 kg 200 mg SQ Q2W \>30-60 kg 300 mg SQ Q2W
Treatment: Eosinophilic Esophagitis (EoE) food introduction-1st, Eosinophilic Esophagitis (E0E) food introduction-2nd, Eosinophilic Esophagitis (EoE) Food introduction-3rd dose, and Dupilumab
Data and sources
- Registry record
- Listed on ClinicalTrials.gov.How to verify a trial in the registry
- Publications
- Efficacy of Dupilumab on Facilitated Food Reintroduction in Eosinophilic Esophagitis.Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association, 2026
- Record updated
- 10 November 2025